Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9079974 | 1.00 | CA12 (0.38) | CA12CA9CA1CA2TSHR | |
| SCHEMBL14472549 | 1.00 | CA12 (0.38) | CA12CA9CA1CA2TSHR | |
| SCHEMBL6280678 | 1.00 | CA12 (0.38) | CA12CA9CA1CA2TSHR | |
| SCHEMBL254392 | 1.00 | CA12 (0.38) | CA12CA9CA1CA2TSHR | |
| SCHEMBL1509203 | 1.00 | CA12 (0.38) | CA12CA9CA1CA2TSHR | |
| SCHEMBL239520 | 1.00 | CA12 (0.38) | CA12CA9CA1CA2TSHR | |
| SCHEMBL15752289 | 1.00 | CA12 (0.38) | CA12CA9CA1CA2TSHR | |
| SCHEMBL8355844 | 1.00 | CA12 (0.38) | CA12CA9CA1CA2TSHR | |
| SCHEMBL254386 | 0.86 | CA12 (0.42) | CA12CA9CA1CA2TSHR | |
| SCHEMBL11548381 | 0.86 | CA12 (0.42) | CA12CA9CA1CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170791-B1 | METHOD FOR PRODUCING CYCLOPENT-4-ENE-1,3-DIOL OR CYCLOPENT-4-ENE-1,3-DIOL DERIVATIVES | EUTICALS GMBH (DE) | 2013-05-08 | — | — | EP | claimed |
| US-20100178678-A1 | Method for producing cyclopent-4-ene-1,3-diol or cyclopent-4-ene-1,3-diol derivatives | ARCHIMICA GMBH (DE) | 2010-07-15 | — | — | US | claimed |
| EP-2170791-A1 | METHOD FOR PRODUCING CYCLOPENT-4-ENE-1,3-DIOL OR CYCLOPENT-4-ENE-1,3-DIOL DERIVATIVES | Archimica GmbH (DE) | 2010-04-07 | — | — | EP | claimed |
| WO-2008151750-A1 | METHOD FOR PRODUCING CYCLOPENT-4-ENE-1,3-DIOL OR CYCLOPENT-4-ENE-1,3-DIOL DERIVATIVES | ARCHIMICA GMBH (DE) | 2008-12-18 | — | — | WO | claimed |
| US-6974834-B2 | Process for preparing enantiomerically enriched (1S,4R) 1-acetoxy-4-hydroxycyclopent-2-ene | AGOURON PHARMACEUTICALS INC. (US) | 2005-12-13 | — | — | US | claimed |
| EP-1587937-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED (1S,4R) 1-ACETOXY-4-HYDROXYCYCLOPENT-2-ENE | Pharmacia & Upjohn Company LLC (US) | 2005-10-26 | — | — | EP | claimed |
| US-20040171129-A1 | Process for preparing enantiomerically enriched (1S,4R) 1-acetoxy-4-hydroxycyclopent-2-ene | AGOURON PHARMACEUTICALS, INC. | 2004-09-02 | — | — | US | claimed |
| WO-2004063384-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED (1S,4R) 1-ACETOXY-4-HYDROXYCYCLOPENT-2-ENE | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-07-29 | — | — | WO | claimed |
| US-12435057-B2 | Triazole carboxylic acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-10-07 | — | — | US | disclosed |
| US-12384768-B2 | Isoxazole carboxylic acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250179027-A1 | CYCLOALKYL OR HETEROCYCLYL SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF | SHENZHEN TARGETRX, INC. (CN) | 2025-06-05 | — | — | US | disclosed |
| EP-4474377-A1 | CYCLOALKYL OR HETEROCYCLYL SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF | Shenzhen TargetRx, Inc. (CN) | 2024-12-11 | — | — | EP | disclosed |
| EP-3986552-B1 | ISOXAZOLE CARBOXYLIC ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2024-09-18 | — | — | EP | disclosed |
| CN-116693458-A | Cycloalkyl or heterocyclyl substituted heteroaryl compounds, compositions and uses thereof | 深圳市塔吉瑞生物医药有限公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-0487657-A1 | PROCESS FOR THE SYNTHESIS OF CYCLOPENTENE DERIVATIVES | GLAXO INC. (US) | 1992-06-03 | — | — | EP | disclosed |
| EP-0475411-A1 | Novel carbocyclic adenosine analogs useful as immunosuppressants | HOECHST MARION ROUSSEL, INC. (US) | 1992-03-18 | — | — | EP | disclosed |
| EP-0475413-A2 | Carbocyclic nucleoside analogs useful as immunosuppressants | HOECHST MARION ROUSSEL, INC. (US) | 1992-03-18 | — | — | EP | disclosed |
| WO-1991015489-A1 | PROCESS FOR THE SYNTHESIS OF CYCLOPENTENE DERIVATIVES | GLAXO INC. (US) | 1991-10-17 | — | — | WO | disclosed |
| US-4132726-A | INTERMEDIATES FOR PROSTAGLANDIN COMPOUNDS | TEIJIN LIMITED (JP) | 1979-01-02 | — | — | US | disclosed |
| US-4008125-A | New cyclopentene-diols and new acyl esters thereof and process for their preparation | TEIJIN LIMITED (JA) | 1977-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435057-B2 | Triazole carboxylic acids as LPA antagonists | LPAR3, LPAR1, LPAR5 | CA12 3211/4885CA9 1754/4885CA1 2567/4885 |
| US-20100178678-A1 | Method for producing cyclopent-4-ene-1,3-diol or cyclopent-4-ene-1,3-diol derivatives | OTUB1, DEK, DECR1 | CA12 1107/4885CA9 760/4885CA1 216/4885 |
| US-12384768-B2 | Isoxazole carboxylic acids as LPA antagonists | LPAR3, LPAR1, LPAR5 | CA12 2473/4885CA9 1205/4885CA1 1739/4885 |
| US-20250179027-A1 | CYCLOALKYL OR HETEROCYCLYL SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF | BTK, LYN, SYK | CA12 3337/4885CA9 2167/4885CA1 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.